Testing brain stimulation with mirror therapy for stroke recovery
Tests a brain stimulation device with mirror therapy in adults recovering from stroke.
Plain-language title generated from the registry record
Registry title: Novel Brain Neurotechnology for Optimizing Precision Mirror Therapy in Stroke
Key facts
- Where
- Taoyuan, TaiwanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 85 years old?
Source: NCT05238272, who can take part
Where in Taiwan
- Chang Gung Memotial HospitalTaoyuan, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chang Gung Memorial Hospital
- Trial code
- NCT05238272
- Record updated
- 14 February 2022
- Original description
The primary aim of this project will be to determine the effects of the tRNS-augmented unilateral and bilateral MT, and their effects relative to the control interventions (sham tRNS with unilateral or bilateral MT) on restoring health outcomes including motor function, daily function, quality of life and self-efficacy, and motor control strategy as well as brain activities (electroencephalography, EEG) in stroke patients.Read full original descriptionShow less
Novel Brain Neurotechnology for Optimizing Precision Mirror Therapy in Stroke
The primary aim of this project will be to determine the effects of the tRNS-augmented unilateral and bilateral MT, and their effects relative to the control interventions (sham tRNS with unilateral or bilateral MT) on restoring health outcomes including motor function, daily function, quality of life and self-efficacy, and motor control strategy as well as brain activities (electroencephalography, EEG) in stroke patients.
Inclusion: ≥ 3 months onset from a first-ever unilateral stroke; an initial FMA scores between 18 to 56, indicating moderate to mild upper extremity motor impairment (Thielman, Kaminski, \& Gentile, 2008); age between 35 to 85; no excessive spasticity in any of the joints of the affected arm (shoulder, elbow, wrist and fingers); ability to follow instructions and perform tasks (Mini Mental State Examination scores ≥24); no participation in any neurorehabilitation experiments or drug clinical trials and; willing to provide written informed consent.
Exclusion: concomitant neurological conditions such as dementia, Parkinson's disease, brain tumor, brain injury and other brain diseases (such as intracranial hypertension or cerebral edema); Botulinum toxin injections 3 months before enrollment; have unstable cardiovascular status such as uncontrolled hypertension or New York Heart Association (NYHA) Class III/IV heart failure or are not suitable for receiving tRNS by the physician's assessments; contradiction to tRNS including a history of epilepsy, pregnant, having pacemakers and metallic implants in the neck and heads (Rossi, Hallett, Rossini, Pascual-Leone, \& Safety of, 2009); History of drug or alcohol abuse(Rossi et al., 2009).